Japan’s Shionogi Seen Defending Self Against Takeover With Sciele Buy
This article was originally published in PharmAsia News
Executive Summary
The acquisition by Japan's Shionogi of U.S. drug maker Sciele Pharma is seen as an attempt to protect itself from being an acquisition target because of its attractive drug pipeline. Isao Teshirogi, Shionogi president, emphasizes the firm's acquisition of a U.S. sales network, but the firm had resisted that move in the past. The company may have changed its attitude when it began to see progress in developing new drug candidates to treat major problems such as obesity and HIV raising its profile and making it a takeover target in the eyes of Western drug makers. (Click here for more - a subscription may be required
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.